The Effect of Parent Mediated Intervention Program on Children With ASD Exposed to Earthquake in Turkey in February 2023
Launched by SABRI HERGÜNER · Aug 9, 2023
Trial Information
Current as of July 05, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a special online program designed to help parents of children with Autism Spectrum Disorder (ASD) who faced challenges after the significant earthquake in Turkey in February 2023. The goal is to see how this group-based intervention can improve the social skills, communication, and learning abilities of children with autism, while also supporting the mental health of their parents. The researchers hope to find effective ways to help these families who have experienced major disruptions in their lives, including changes in education and living situations.
To participate in this study, children must be diagnosed with autism by a specialist and be between 2 and 6 years old. They should also live in one of the 10 provinces that felt the earthquake's impact. Unfortunately, children with certain genetic diseases will not be eligible for this trial. Parents involved can expect to learn new strategies to support their child's development and improve their interactions at home. This program aims to provide valuable tools and support to families during a difficult time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The diagnosis of autism must be made by a specialist
- • Being in the age range of 24-72 months
- • Living in one of the 10 provinces where the earthquake was felt intensely during the earthquake
- Exclusion Criteria:
- • Having a genetic disease
About Sabri Hergüner
Sabri Hergüner is a distinguished clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a strong commitment to ethical practices and regulatory compliance, the organization collaborates with leading healthcare professionals and research institutions to design and execute robust clinical trials. Leveraging extensive expertise in various therapeutic areas, Sabri Hergüner strives to facilitate the development of groundbreaking treatments, ensuring that safety and efficacy remain at the forefront of their mission. Their proactive approach to stakeholder engagement and data integrity underscores their reputation as a trusted partner in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, , Turkey
Patients applied
Trial Officials
Sabri Hergüner, Assoc.
Study Director
Hergüner Therapy Privat Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported